XBiotech Inc. (XBIT)
| Market Cap | 57.62M -10.8% |
| Revenue (ttm) | n/a |
| Net Income | -45.13M |
| EPS | -1.48 |
| Shares Out | 30.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,248 |
| Open | 1.880 |
| Previous Close | 1.870 |
| Day's Range | 1.860 - 1.946 |
| 52-Week Range | 1.800 - 3.440 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About XBIT
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquarte... [Read more]
Financial Performance
Financial StatementsNews
XBiotech elects Jan-Paul Simard to serve as co-CEO
XBiotech (XBIT) announced that its board of directors have elected Jan-Paul Simard to serve as co-CEO alongside CEO Sushma Shivaswamy, effective Oct. 23. Shivaswamy has been with XBiotech for 17…
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside ...
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.
XBiotech to enroll patients in vilamakitug trial following FDA review
XBiotech (XBIT) announced that its investigational new drug, or IND, application for V-SPINE, a Phase II, double-blind, placebo-controlled, randomized study evaluating the efficacy and safety of vilam...
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
XBiotech pauses rheumatology program
XBiotech (XBIT) is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized s...
XBiotech trading halted, news pending
08:55 EST XBiotech (XBIT) trading halted, news pending
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
XBiotech announces data from Phase 1/2 1-BETTER study
XBiotech announced data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix antibody...
XBiotech trading halted, volatility trading pause
11:35 EDT XBiotech trading halted, volatility trading pause
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Bett...
XBiotech to begin constructing new R&D facility on 48-acre campus
XBiotech announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to...
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and developmen...
XBiotech announces Kivitz is now Lead Investigator, Study Chairman
XBiotech announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthr...
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation)
XBiotech announces enrollment completion of Phase I trial for Hutrukin
XBiotech announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I ...
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The...
XBiotech announces enrollment completion of Phase II study for Natrunix
XBiotech announced the completion of enrollment of the Phase II portion of its 1-BETTER study-a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with ...
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-con...
XBiotech treats first patient in Phase II RA trial of Natrunix
XBiotech began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause ...
XBiotech announces first subject enrollment in Phase I trial for Hutrukin
XBiotech has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Emergency use of "clot-busti...